Article

CK improves near vision in post-LASIK and plano presbyopic eyes

NearVision conductive keratoplasty (CK) (Refractec) offers a minimally invasive method of enhancing near vision in plano presbyopes and in post-LASIK eyes.

NearVision conductive keratoplasty (CK) (Refractec) offers a minimally invasive method of enhancing near vision in plano presbyopes and in post-LASIK eyes, according to the results of an FDA presbyopia study and a CK post-LASIK study, as presented by Marguerite McDonald of Tulane University School of Medicine, New Orleans, USA.

During the FDA CK presbyopia study, 188 eyes of 150 patients were treated. At 24 months, there was good preservation of best spectacle corrected visual acuity (BCVA) with no eyes losing two or more lines of vision. No complications or adverse events were recorded. Fifty-three percent of eyes were within 0.50 D of intended correction and 91% were within 1 D. Uncorrected visual acuity (UCVA) results showed that 75% of eyes were J3 or better at 24 months and 51% were J2 or better.

In the post%LASIK study, 150 eyes of 150 patients were treated with CK at least one year after LASIK. By three months follow-up, no patients has lost two or more lines of vision or had a best spectacle corrected visual acuity (BSCVA) of 20/40 or worse. Ninety-six percent of patients achieved an uncorrected near vision of J3 or better, with 75% reading at J1 or better.

These results demonstrate that CK is an effective method of enhancing near vision in plano presbyopes and post-LASIK eyes.

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Related Videos
(Image credit: Ophthalmology Times) ASCRS 2025: Mark Lobanoff, MD, on making the move to office-based surgery
Barsha Lal, PhD, discusses the way low dose atropine affects accommodative amplitude and dynamics at the 2025 ARVO meeting
(Image credit: Ophthalmology Times) NeuroOp Guru: When eye findings should prompt neuroimaging in suspected neuro-Behcet disease
At the Association for Research in Vision and Ophthalmology (ARVO) meeting, Katherine Talcott, MD, a retina specialist at Cleveland Clinic, shared her findings on EYP-1901 (EyePoint Pharmaceuticals) in the phase 2 DAVIO study.
Dr. Jogin Desai, founder of Eyestem Research, discusses his research at the Association for Research in Vision and Ophthalmology.
(Image credit: Ophthalmology Times) ASCRS 2025: Michael Rivers, MD, shares his takeaways as a panelist at the inaugural SightLine event
(Image credit: Ophthalmology Times) ASCRS 2025: Karl Stonecipher, MD, on LASIK outcomes using an aspheric excimer laser for high myopia
John Tan talks about an emergency triage framework for retinal artery occlusion at the 2025 Association for Research in Vision and Ophthalmology (ARVO) meeting.
Dr Robert Maloney at the 2025 Controversies in Modern Eye Care meeting
Wendy Lee, MD, MS, at Controversies in Modern Eye Care 2025.
© 2025 MJH Life Sciences

All rights reserved.